Pharmaceutical giant Eli Lilly’s experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report. Findings from the phase 1 trial with Eli Lilly’s lipodisiran drug found that the highest dose reduced a heart disease-linked protein — that functions similarly to LDL, known as...
